Dear All:
To start the new year, I’ve learned that Pew has updated their pipeline analysis. First released in Feb 2014, it has been steadily updated ever since. This newest analysis has a data cut-off of Sep 2017 and covers both traditional antibiotics as well as non-traditional products. All the links you need are just below my signature, but let me point out a few highlights:
- Separate commentaries are provided on the state of the traditional and non-traditional pipeline.
- An excellent infographic is provided. Here’s a little piece of it. Combined with the idea that at most 1 in 5 of these products will reach registration, you have a very scary story indeed
- As you know, WHO has also recently published a pipeline analysis. The two analyses are complementary and we have a joint blog from the organizations.
- Pew’s analysis extends that of WHO by covering non-traditional products such as vaccines, microbiome products, immune enhancers, and more. There are 32 of these underway right now. As these are challenging and high-risk products to develop, I am glad to see this level of effort.
- If you are interested in doing your own analytics, note that the pipeline charts are interactive and can be sorted by development phase, drug class, pathogen coverage, and more. You can also download past versions of the pipeline tables.
Core message: We have a pipeline, but it remains VERY thin. Let’s all get busy and see what can be developed to address the problem of antibiotic resistance!
All best wishes, –jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/
Pew’s Dec 2017 Traditional/Small Molecule Antibiotics Analyses
- Interactive chart: Antibiotics Currently in Global Clinical Development
- Analysis: Tracking the Global Pipeline of Antibiotics in Development
- Joint blog with WHO: The World is Running Out of Antibiotics
- Infographic: The Critical Need for New Antibiotics
Pew’s Dec 2017 Nontraditional Products Analyses
- Interactive chart: Nontraditional Products for Bacterial Infections in Clinical Development
- Analysis: Assessment of Nontraditional Products in Development to Combat Bacterial Infections
Upcoming meetings of interest to the AMR community:
- 11 Jan 2018 (Washington): FDA AMDAC on Aradigm’s inhaled ciprofloxaxcin for non-CF bronchiectasis
- [NEW] 18 Jan 2018 (Geneva): Release of the First Annual Progress Report in support of the UN Sustainable Development Goals (SDG 3 in particular) by the AMR Industry Alliance
- 12-14 Feb 2018 (Baltimore): ASM Biothreats Conference
- 28 Feb 2018 (Brussels): Deadline for responses to IMI2 Call 13 (Topic 3) on AMR diagnostics
- 11-16 Mar 2018 (Ventura Beach): Gordon Research Conference on Antibacterial Discovery
- 21-24 Apr 2018 (Madrid): ECCMID
- 7-11 Jun 2018 (Atlanta): ASM Microbe
- 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
- 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal) (initial flyer)
- 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France) (link to 2017 program — details pending for 2018)
